HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to fight breast cancer in the brain
Disease control TerminatedThis study tested whether adding a new drug called ASLAN001 to an existing chemotherapy (capecitabine) could help control breast cancer that had spread to the brain and was getting worse despite prior radiation. It was for patients with a specific type of breast cancer called HER…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Apr 03, 2026 21:41 UTC
-
New drug combo tested for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called BDC-1001, both by itself and combined with an existing immunotherapy drug (nivolumab), for people with advanced cancers that have a specific marker called HER2. The main goals were to find safe doses and see if the treatments could …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Could some breast cancer patients avoid surgery altogether?
Disease control TerminatedThis study explored whether women with a specific type of early-stage, HER2-positive breast cancer could safely skip surgery and lymph node removal. To qualify, patients first needed to have no detectable cancer left after completing a standard course of targeted drug therapy. Th…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fundacio Clinic Barcelona • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Trial for tough breast cancer cases halted early
Disease control TerminatedThis study tested an experimental drug called BDC-1001, both alone and combined with an existing drug (pertuzumab), for people with advanced HER2-positive breast cancer that had worsened after standard treatments. The goal was to see if the treatment could shrink tumors and was s…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Early halt for brain cancer combo trial
Disease control TerminatedThis early-stage study aimed to see if combining three cancer drugs with a precise type of radiation could better control breast cancer that had spread to the brain. It was designed for people with a specific type of breast cancer (HER2-positive) and up to 10 small brain tumors. …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC